- Merck (NYSE:MRK) and Ridgeback Biotherapeutics have announced that molnupiravir (EIDD-2801/MK-4482), their investigational oral antiviral agent against COVID-19, managed to speed up the time for the infectious agent to become negative in COVID-19 patients.
- The preliminary data from the Phase 2a study were
Merck announces positive mid-stage trial data for COVID-19 antiviral drug
Recommended For You
About MRK Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| MRK | - | - |
| Merck & Co., Inc. | ||